Medlumics is a technology company.
Medlumics has raised $64.0M across 3 funding rounds.
Medlumics has raised $64.0M in total across 3 funding rounds.
Medlumics has raised $64.0M in total across 3 funding rounds.
Medlumics's investors include Andera Partners, Alta Life Sciences, Sanofi Ventures, Ysios Capital.
MedLumics is a Madrid-based medical technology company developing catheter-based systems for treating cardiac arrhythmias, particularly supraventricular tachycardias and atrial fibrillation (AF). Its flagship product, the AblaView® Optically Guided Pulsed Field Ablation (PFA) system, combines irreversible electroporation and radiofrequency ablation with real-time optical imaging to enable precise lesion formation during procedures.[1] The company serves trained healthcare professionals in the cardiology sector, addressing high recurrence rates (over 60% at one year) from ineffective ablations by providing direct visualization of tissue changes, with $62.99M raised to date and recent completion of a successful First-In-Man (FIM) study showing efficacy at three months.[1][2]
MedLumics operates at Series D stage, focusing on its integrated optics platform that merges optical and electrical components for high-quality, real-time imaging during ablations, with a pipeline for additional cardiac applications.[1]
MedLumics was founded around 2009-2011 in Madrid, Spain, as an ISO13485 and ISO9001 certified medical device company specializing in optically guided devices powered by biophotonics and proprietary integrated optics technology.[1][3][4] The core idea emerged from advancing optical coherence tomography (OCT) and polarization-sensitive optical coherence reflectometry to overcome limitations in catheter ablation for AF, where poor lesion formation leads to pulmonary vein reconnection and high recurrence.[2]
Early milestones include a 2014 dermatology spinout (NITID skin imaging system via DermaLumics) and a 2015 pre-clinical feasibility study validating real-time OCT for RF ablation, published in the Journal of Innovations in Cardiac Rhythm Management.[2] Pivotal recent progress: December 2024 announcement of FIM study completion for AblaView®, presented at AF Symposium 2025, demonstrating successful remapping at three months.[1]
MedLumics rides the wave of advanced electrophysiology tools transforming interventional cardiology, where PFA and imaging-guided ablations address unmet needs in AF treatment—a market strained by 60%+ recurrence rates and procedural complexity.[2] Timing aligns with surging demand for non-thermal PFA (safer than RF alone) and real-time diagnostics, fueled by aging populations and rising arrhythmia prevalence. Market forces like regulatory approvals in Europe and investor backing (e.g., VI Partners) favor its optics platform, influencing the ecosystem by setting standards for visually confirmed lesions, potentially lowering costs and improving outcomes in a field dominated by indirect monitoring tools.[1][2]
MedLumics is poised for regulatory milestones and commercialization of AblaView®, with its FIM success signaling strong clinical validation and expansion into broader AF and arrhythmia markets.[1] Trends like AI-enhanced imaging and hybrid ablation will amplify its edge, evolving its influence from innovator to category leader as adoption reduces recurrence benchmarks. This positions MedLumics to redefine catheter precision, echoing its optical roots in tackling cardiology's toughest visibility challenges.
Medlumics has raised $64.0M across 3 funding rounds. Most recently, it raised $22.0M Venture Round in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $22.0M Venture Round | Andera Partners | |
| Mar 1, 2017 | $37.0M Series B | Alta Life Sciences, Andera Partners, Sanofi Ventures, Ysios Capital | |
| Nov 1, 2011 | $5.0M Series A | Alta Life Sciences, Sanofi Ventures, Ysios Capital |